ZDF
Sign inSign up

Vulnerabilities

Vulnerability · CVE-2026-34619

ColdFusion versions 2023.18, 2025.6 and earlier are affected by an Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') vulnerability that co…

Published Apr 14, 2026 · catalog updated Aug 28, 2026 · the affected product

Check if you run it

No confirmed exploitation is on record for CVE-2026-34619. EPSS is 1.14%. Act only if a listed version of the affected product is installed.

Gaps on this record

  • No plain product name is stored. The page cannot tell you which product to check.
  • No version range is stored. A customer cannot check an installed version against this record.
  • No vendor fix or required action is stored. Compare the linked advisory before you change production.
Severity
High7.7
Known exploitation
Not in CISA/VulnCheck KEV
EPSS
1.14%
Remediation
Advisory link
Affected products
cpe adobe/coldfusion

ColdFusion versions 2023.18, 2025.6 and earlier are affected by an Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') vulnerability that could result in a Security feature bypass. An attacker could leverage this vulnerability to access unauthorized files or directories outside the intended restrictions. Exploitation of this issue does not require user interaction.

Are you affected?

Enter the version you run. The result uses only the ranges stored on this record.

The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.

  • cpe adobe/coldfusion2023

How to fix CVE-2026-34619

What to do

Three questions, each answered from this record only. Confirm the vendor advisory before you patch.

Should you patch?

No confirmed exploitation is on record for CVE-2026-34619. EPSS is 1.14%. Act only if a listed version of the affected product is installed.

Which versions are affected?

Compare what you have installed with 2023. Compare the installed version with the linked vendor advisory before you change production.

What should an analyst verify?

CWE-22: Path Traversal. EPSS 1.14%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.

Code

The project this record applies to. Exploit listings stay in References.

No public source repository is identified for this product.

Timeline

Detection, updates, and resolution for this record.

  1. Apr 14, 2026 · NIST NVD

    Detected

    ColdFusion versions 2023.18, 2025.6 and earlier are affected by an Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') vulnerability that could result in a Security feature bypass. An attacker could leverage this vulnerability to access unauthorized files or directories outside the intended restrictions. Exploitation of this issue does not require user interaction.

  2. Aug 28, 2026 · NIST NVD

    Updated

    ColdFusion versions 2023.18, 2025.6 and earlier are affected by an Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') vulnerability that could result in a Security feature bypass. An attacker could leverage this vulnerability to access unauthorized files or directories outside the intended restrictions. Exploitation of this issue does not require user interaction.

Sources

  • CVE.orgVulnerability recordCVE-2026-34619

    Official CVE identifier

    cve.org
  • FIRST EPSSExploitation probabilityCVE-2026-34619

    30-day exploitation probability 1.1%

    first.org
  • NIST NVDVulnerability recordCVE-2026-34619

    ColdFusion versions 2023.18, 2025.6 and earlier are affected by an Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') vulnerability that could result in a Security feature bypass. An attacker could leverage this vulnerability to access unauthorized fil

    nvd.nist.gov

References

Freshness

Last verified in this catalog Oct 18, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.